Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Current Deferred Revenue (2024 - 2025)

Exagen (XGN) has disclosed Current Deferred Revenue for 2 consecutive years, with $700000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 4.5% year-over-year to $700000.0, compared with a TTM value of $700000.0 through Dec 2025, down 4.5%, and an annual FY2025 reading of $700000.0, down 4.5% over the prior year.
  • Current Deferred Revenue was $700000.0 for Q4 2025 at Exagen, up from $641000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.0 million in Q2 2025 and bottomed at $641000.0 in Q3 2025.